News | Stents Drug Eluting | January 10, 2017

Medinol Announces Positive 12-Month Trial Results for EluNIR Drug-Eluting Stent

Elastomer-coated DES shows identical target lesion failure, low definite/probable stent thrombosis rate compared to Resolute Integrity stent

Medinol, BIONICS study, 12-month results, TCT 2016, drug-eluting stent, EluNIR

January 10, 2017 — Medinol announced in December positive twelve-month clinical results from the BIONICS study. The study was conducted to evaluate EluNIR, Medinol's novel coronary stent system and the first ever elastomer-coated drug eluting stent (eDES), according to the company.

This global pivotal study enrolled 1,919 patients from 76 sites in eight countries. The BIONICS results were highlighted in the opening Late Breaking Trial session of the 28th annual Transcatheter Cardiovascular Therapeutics (TCT2016) scientific symposium, Oct. 29-Nov. 2 in Washington, D.C. The study data will be submitted to the U.S. Food and Drug Administration (FDA) to support the U.S. regulatory approval of EluNIR for the treatment of patients with narrowing or blockage of their coronary arteries.

The BIONICS study — a global, prospective, randomized, multicenter, non-inferiority clinical trial — was designed to include a "more comers" population, i.e. one that closely represents the real-world patient population. The EluNIR Stent (study name BioNIR) was compared to the Resolute Integrity Stent (1:1 randomization). Key results from the study include:

  • For its primary endpoint of target lesion failure (TLF), EluNIR demonstrated a rate of 5.4 percent at 12 months compared to an identical rate of 5.4 percent for Resolute (p=0.0013 for non-inferiority). TLF was defined as the composite of cardiac death, target vessel MI and clinically driven TLR; and
  • Good safety profile, with a low definite/probable stent thrombosis rate of 0.4 percent for EluNIR, compared to 0.8 percent for Resolute (p=NS), with no events beyond 30 days for EluNIR.    

"The BIONICS data validated that the EluNIR stent performed very well in a more broad, less selected 'more comers' population than has previously been studied for most other DES," said David Kandzari, M.D., F.A.C.C., director of interventional cardiology at Piedmont Heart Institute, Atlanta, and principal investigator for the BIONICS trial. "These results establish the excellent clinical performance of this stent, and we look forward to seeing the angiographic data over the next few months to further support its efficacy."

In addition to the BIONICS study, new twelve-month data from NIREUS, the European pivotal trial for EluNIR, were presented at TCT. The NIREUS study — a prospective, multi-center, randomized, non-inferiority pivotal study comparing EluNIR to the Resolute Integrity Stent — met its non-inferiority primary endpoint of angiographic in-stent late loss at six months. These data were presented at EuroPCR in May 2016. The recent twelve-month clinical data, presented TLF of 3.4 percent for EluNIR and 5.9 percent for Resolute (p=NS).These outcomes were consistent with the positive results of BIONICS.

For more information: www.medinol.com

Related Content

First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Technology | Intra-Aortic Balloon Pumps (IABP)| May 02, 2017
May 2, 2017 — The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the Teleflex Inc.
a list of SCAI late breaking trial presentations
Feature | SCAI| May 01, 2017
May 1, 2017 — The Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions will take
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
the Impella pVAD improves survival, mortality in AMI heart attack with cardiogenic shock

Early use of the Impella percutaneous ventricular assist device prior to angioplasty may significantly improve survival for patients in cardiogenic shock.

Feature | Hemodynamic Support Devices| April 28, 2017 | Dave Fornell
Recent clinical study data presented at the American College of Cardiology (ACC) 2017 meeting show new treatment prot
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
microbleeds, brain bleeds caused by TAVR

An MRI brain scan showing multiple microbleeds in a transcatheter aortic valve replacement (TAVR) patient from the study.

Feature | Heart Valve Technology| March 23, 2017
March 22, 2017 — A quarter of the patients in a single-center study of 84 patients undergoing transcatheter aortic va
Overlay Init